Methods
cSCC
This is a single-center, non-randomized, open label, exploratory study designed to investigate the efficacy and safety of a stepwise conversion from CNI- to SRL-based therapy on the incidence and severity of new cSCC in kidney transplant recipients over 36 months of follow-up. The endpoints of interest were compared to a non-randomized control group of patients with high-risk cSCC but unsuitable/not willing for conversion, as detailed below.This study was conducted in accordance with the Declaration of Helsinki and the International Good Clinical Practices guidelines and was approved by the local ethics committee (CAEE: 40254114.5.0000.5505). All patients provided written informed consent before enrollment.